Polyoxidovanadates as a pharmacological option against brain aging

Area of Science:

• Neuroscience
• Pharmacology
• Gerontology

Background:

• Global population aging is associated with increased chronic diseases like neurodegenerative disorders.
• Oxidative stress and neuroinflammation are key factors contributing to age-related cognitive decline.
• Polyoxidovanadates (POVs) exhibit potential pharmacological benefits against chronic diseases.

Purpose of the Study:

• To investigate the effects of POVs on hippocampal neuroinflammation, redox balance, and recognition memory in aging rats.
• To compare the efficacy of decavanadate (DV) and a Metformin-Decavanadate combination (MetfDeca) against aging-related neuronal damage.

Main Methods:

• Aging rats (18 months old) received daily doses of sodium metavanadate (MV), decavanadate (DV), Metformin (Metf), or MetfDeca for two months.
• Evaluated short-term and long-term recognition memory.
• Assessed hippocampal levels of reactive oxygen species (ROS), inflammatory markers (IL-1β, TNF-α), lipid peroxidation, antioxidant enzyme activity (SOD, catalase), and neuronal markers (Nrf2, GFAP).

Main Results:

• DV, Metf, and MetfDeca treatments significantly improved recognition memory, reduced hippocampal ROS, IL-1β, and TNF-α levels, and ameliorated lipid peroxidation.
• Antioxidant enzyme activity (superoxide dismutase and catalase) increased substantially in DV, Metf, and MetfDeca groups.
• POV treatments effectively reduced Nrf2 and GFAP immunoreactivity in key hippocampal regions (CA1, CA3, DG), with Metformin showing a minor effect and MV showing no improvement.

Conclusions:

• Decavanadate (DV) and Metformin-Decavanadate (MetfDeca) demonstrate significant potential in mitigating age-related neuronal damage.
• These POV treatments offer a promising therapeutic strategy, with significantly lower doses required compared to Metformin.
• DV and MetfDeca could be valuable pharmacological options for reducing neuroinflammation and oxidative stress associated with aging.